DiaMedica Therapeutics (DMAC) Net Equity Issued and Repurchased (2020 - 2025)

DiaMedica Therapeutics' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $11.8 million for Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $11.8 million in Q4 2025; TTM through Dec 2025 was $43.3 million, a 1082150.0% increase from a year earlier, with the FY2025 full-year figure at $43.3 million, up 268.45% from the prior year.
• Net Equity Issued and Repurchased slipped to $11.8 million in Q4 2025 per DMAC's latest filing, from $31.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $31.5 million in Q3 2025 and bottomed at -$18000.0 in Q4 2021.
• The 3-year median for Net Equity Issued and Repurchased is $11.8 million (2025), against an average of $14.6 million.
• Biggest YoY gain for Net Equity Issued and Repurchased was 73.13% in 2021; the steepest drop was 40.95% in 2021.
• Year by year, Net Equity Issued and Repurchased stood at -$18000.0 in 2021, then surged by 77.78% to -$4000.0 in 2023, then jumped by 293975.0% to $11.8 million in 2025.
• Per Business Quant, the three latest DMAC Net Equity Issued and Repurchased figures stand at $11.8 million (Q4 2025), $31.5 million (Q3 2025), and -$4000.0 (Q3 2023).